Company
SGX Catalist:9G2
Operates a single-site Singapore medical centre built around advanced imaging and radiation oncology. Two reported segments: medical diagnostics and treatments (cancer diagnostics, nuclear medicine, general health screening, aesthetic services) and radiation therapy and medical oncology (proton beam therapy, photon radiation therapy, medical oncology). Its stated clinical focus spans cancer, neurodegenerative and cardiovascular disease detection. The longevity-relevant part is the diagnostics and imaging arm: high-resolution and nuclear-medicine imaging plus paid health screening is early-detection infrastructure, the same category as preventive screening plays. The proton-beam oncology business is treatment for existing disease, not a longevity intervention, and is the larger capital commitment. There is no geroscience, biomarker-of-ageing, or therapeutic-development activity here. It is a small, loss-making clinical operator: FY2025 revenue SGD 15.71m, down 5.6% year on year, with a net loss of SGD 27.05m, and a market capitalisation under SGD 50m. Note the corporate site www.sam.com.sg did not resolve on repeated attempts, so the business description above rests on exchange-data aggregators rather than company disclosure.
Thesis
Market data
| Metric | Detail |
|---|---|
| Exchange | SGX Catalist |
| Ticker | SGX Catalist:9G2 |
| Secondary listing | None |
| Market cap | approx. SGD 47 million (17 July 2026) |
| Status | Listed and trading |
Get in touch
Offering
No commercial services are recorded for this company yet.
Recent inflection
FY2025 results (financial year ended 31 December 2025) showed revenue of SGD 15.71m, down 5.63% year on year, with a net loss of SGD 27.05m, narrower than FY2024. The shares traded at SGD 0.027 on 17 July 2026, down 6.9% year to date, with the next earnings report scheduled for 29 August 2026 (stockanalysis.com, retrieved 19 July 2026).
Keep reading
Sources
Every entity profile on variis is sourced. Not investment advice.